On August 5, Eli Lilly rose 5.71% in regular trading, trading at $1195.503/share, with turnover of $802 million. The surge was driven by the company's Q2 financial results that substantially exceeded market expectations across all key metrics.

Eli Lilly reported Q2 adjusted EPS of $8.38, beating the consensus estimate of $6.01 by 39.4%, and up from $6.31 a year earlier. Revenue reached $22.97 billion, surpassing the $20.69 billion estimate, representing a 48% year-over-year increase. Core product Mounjaro delivered quarterly revenue of $9.9 billion, up 91% year-over-year and well above the $8.83 billion estimate. Zepbound generated $4.9 billion in revenue, a 46% annual increase.

The company raised its full-year revenue guidance to $85-$87 billion from $82-$85 billion previously, above the FactSet consensus of $85.28 billion. Additionally, CVS Health announced a collaboration with Eli Lilly to expand GLP-1 medication access through transparent pricing and same-day pharmacy pickup, further reinforcing confidence in the demand trajectory. Eli Lilly also announced an additional $4.5 billion investment in manufacturing expansion.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)